• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

    2/9/22 3:43:30 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COLL alert in real time by email
    SC 13G/A 1 tv0630-collegiumpharmaceutic.htm SCHEDULE 13G/A collegiumpharmaceuticalinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  Collegium Pharmaceutical Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  19459J104

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  19459J104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    73,316

    7.  SOLE DISPOSITIVE POWER

    2,191,320

    8.  SHARED DISPOSITIVE POWER

    96,097

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,287,417

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.62%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Collegium Pharmaceutical Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    100 Technology Center Drive, Suite 300
    Stoughton, MA 02072

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    19459J104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $COLL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COLL

    DatePrice TargetRatingAnalyst
    1/10/2025$46.00Hold → Buy
    Needham
    7/30/2024$47.00Neutral → Buy
    H.C. Wainwright
    6/7/2024$41.00 → $44.00Hold → Buy
    Jefferies
    5/10/2024Buy → Hold
    Needham
    5/10/2024$39.00Overweight → Neutral
    Piper Sandler
    1/4/2024$30.00 → $37.00Buy → Hold
    Jefferies
    8/25/2023$35.00 → $36.00Buy
    Needham
    5/2/2023$30.00Buy
    Jefferies
    More analyst ratings

    $COLL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook

    – Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to $455 Million – – Ended Q2'25 with Cash, Cash Equivalents and Marketable Securities of $222.2 Million – – Board of Directors Authorized $150 Million Share Repurchase

    8/7/25 7:30:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

    STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q2 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the C

    7/24/25 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Announces $150 Million Share Repurchase Program

    STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board of Directors has authorized a new share repurchase program to repurchase up to $150 million in common stock through December 31, 2026. This program replaces a previous $150 million share repurchase program authorized in January 2024 which expired on June 30, 2025, and had $65 million remaining under the program. "Collegium's strong financial position provides us with significant flexibility in executing our capital allocation strategy,"

    7/7/25 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.

    SCHEDULE 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    8/13/25 4:05:48 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.

    SCHEDULE 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    8/11/25 4:49:03 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.

    SCHEDULE 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    8/7/25 4:27:45 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Santini Gino sold $201,018 worth of shares (5,405 units at $37.19) and exercised 15,000 shares at a strike of $13.45, increasing direct ownership by 11% to 95,042 units (SEC Form 4)

    4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

    8/19/25 5:10:43 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Commercial Officer Dreyer Scott exercised 4,861 shares at a strike of $21.34 and sold $184,881 worth of shares (4,861 units at $38.03) (SEC Form 4)

    4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

    8/15/25 5:08:54 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Rubric Capital Management Lp sold $946,250 worth of shares (25,000 units at $37.85) (SEC Form 4)

    4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)

    8/15/25 4:12:20 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Collegium Pharmaceutical upgraded by Needham with a new price target

    Needham upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $46.00

    1/10/25 8:00:15 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Pharmaceutical upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Collegium Pharmaceutical from Neutral to Buy and set a new price target of $47.00

    7/30/24 6:32:12 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Pharmaceutical upgraded by Jefferies with a new price target

    Jefferies upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $44.00 from $41.00 previously

    6/7/24 7:29:08 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    3/26/25 7:00:00 AM ET
    $AVTX
    $BHVN
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Announces Updates to its Board of Directors and Executive Leadership Team

           – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company, today announced updates to its Board of Directors and appointments of three new executive leaders as the C

    3/17/25 7:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Appoints Nancy S. Lurker to its Board of Directors

    STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. "Collegium is pleased to welcome Nancy to our Board of Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Nancy's expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions." "This is a pivotal and exciting time for Collegium as it embarks on a new stage of growth

    2/5/25 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Collegium Pharmaceutical Inc.

    SC 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    11/13/24 5:13:28 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc.

    SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    11/13/24 4:30:24 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Collegium Pharmaceutical Inc. (Amendment)

    SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)

    2/14/24 12:04:28 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COLL
    Financials

    Live finance-specific insights

    View All

    Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook

    – Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to $455 Million – – Ended Q2'25 with Cash, Cash Equivalents and Marketable Securities of $222.2 Million – – Board of Directors Authorized $150 Million Share Repurchase

    8/7/25 7:30:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

    STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q2 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the C

    7/24/25 8:00:00 AM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

    – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Confer

    5/8/25 4:01:00 PM ET
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care